$31.5M to spur public health work
October 7, 2013 in Medical Technology
Several big name hospitals, including Cleveland Clinic, Boston Children’s and several University of California entities, recently landed National Institutes of Health funding to speed innovations in public health.
NIH launched a major initiative to improve how basic science advances and discoveries are translated into commercially viable products that improve patient care and advance public health.
NIH Centers for Accelerated Innovations, funded by NIH’s National Heart, Lung, and Blood Institute, will target technologies to improve the diagnosis, treatment, management, and prevention of heart, lung, blood, and sleep disorders.
“The NCAIs will foster a transformational change in the way basic science discoveries move from the laboratory into commercial products,” said Gary H. Gibbons, director of NHLBI, in a news release. “These centers essentially will offer a one-stop shop to accelerate the translation of early-stage technologies for further development by the private sector and ultimate commercialization. As a result, the public will gain access sooner to new biomedical products that improve human health while also benefiting from the economic growth associated with the creation of new companies and the expansion of existing ones.”
NHLBI issued grants totaling $31.5 million to establish three inaugural, multi-institution NCAIs.
- Boston Biomedical Innovation Center: Brigham and Women’s Hospital, Boston Children’s Hospital, Massachusetts General Hospital, and President and Fellows of Harvard College
- Cleveland Clinic Innovation Accelerator: The Cleveland Clinic Lerner College of Medicine; Case Western Reserve University, Cleveland; Cincinnati Children’s Hospital; The Ohio State University, Columbus; and University of Cincinnati
- UC BRAID Center for Accelerated Innovation: University of California, Los Angeles; University of California, Davis; University of California, Irvine; University of California, San Diego; and University of California, San Francisco
NCAIs will provide an integrated, systematic, and comprehensive approach to navigating the translation of early stage biomedical innovations from the research laboratory to commercial development and successful deployment to patients. Each center will be a consortium of academic, government, non-profit, and private sector organizations that will provide funding for feasibility studies; regulatory, legal, and business development expertise; and entrepreneurial training and mentorship. To enhance the scope and impact of the NHLBI investment, each awardee has secured non-federal funding equal to or greater than the NHLBI award.
NCAI awardees will leverage existing federal government resources, including those offered by NIH and by other federal program partners including the U.S. Food and Drug Administration, the United States Patent Office, and the Centers for Medicare Medicaid Services.